Back to top
more

Celgene Corporation (CELG)

(Delayed Data from NSDQ)

$96.88 USD

96.88
5,654,306

+1.67 (1.75%)

Updated May 3, 2019 04:00 PM ET

After-Market: $96.84 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks News

Celgene's Otezla Gains Positive Recommendation from NICE

Celgene Corporation (CELG) announced that the National Institute for Health and Care Excellence (NICE) has issued a final appraisal determination, recommending the use of its oral phosphodiesterase 4, Otezla.

    Juno Gets Breakthrough Therapy Status for Lymphoma Drug

    Juno Therapeutics, Inc. (JUNO) and partner Celgene Corporation (CELG), announced that the FDA has granted Breakthrough Therapy designation to their investigational candidate, JCAR017.

      Celgene (CELG) Otezla Approved in Japan for Two Indications

      Celgene's (CELG) Otezla approved for the treatment of plaque psoriasis and psoriatic arthritis in Japan.

        Agios Stops Development of PKR Activator AG-519, Stock Falls

        Shares of Agios (AGIO) tanked 19.4% after the company decided to discontinue the development of its PKR activator, AG-519.

          The Zacks Analyst Blog Highlights: Celgene, Regeneron Pharmaceuticals, Ophthotech and Exelixis

          The Zacks Analyst Blog Highlights: Celgene, Regeneron Pharmaceuticals, Ophthotech and Exelixis

            Arpita Dutt headshot

            3 Great Stocks to Beat the Biotech Blues

            Are you on the lookout for some good biotech stocks this month? Here are three that warrant a look.

              Corcept Korlym Positive in Phase I/II Breast Cancer Study

              Corcept Therapeutics (CORT) announced encouraging efficacy data from a phase I/II study on Korlym in patients with metastatic triple-negative breast cancer.

                Stock Market News for December 09, 2016

                Markets finished at record highs again on Thursday following ECB's announcement about trimming bond-buying volume and the continuing Trump induced rally.

                  Stock Market News for December 08, 2016

                  The Trump induced rally continued to boost major benchmarks to finish at all-time record highs on Wednesday offsetting the decline in healthcare stocks.

                    Arpita Dutt headshot

                    Biotech Stock Roundup: Actelion Remains in M&A Spotlight, ASH Data in Focus

                    This week, several biotech companies were present at the annual meeting of the American Society of Hematology (ASH) with data on approved and pipeline candidates.

                      Juno Reports Positive Phase I Study Data on Lymphoma Drug

                      Juno Therapeutics, Inc. (JUNO) announced encouraging preliminary clinical data from a phase I study (TRANSCEND) on its lead pipeline candidate, JCAR017, for the treatment of patients non-Hodgkin lymphoma (NHL).

                        Acceleron, Celgene Present Myelodysplastic Syndromes Data

                        Acceleron (XLRN) and Celgene (CELG) announced updated data from the ongoing phase II studies on luspatercept in myelodysplastic syndromes patients.

                          bluebird Stock Up on Positive Interim Multiple Myeloma Data

                          bluebird bio (BLUE) reported encouraging interim phase I data on its anti-BCMA CAR T cell candidate, bb2121, in relapsed/refractory multiple myeloma patients.

                            Madeleine Johnson headshot

                            Here's Why Bluebird Bio (BLUE) is Rallying Today

                            On Thursday, shares of Bluebird Bio Inc. (BLUE) are rallying, up over 17% in midday trading after positive results came in for its experimental anti-BCMA CAR (chimeric antigen receptor) T-cell product candidate bb2121.

                              NVIDIA, Sotheby's Holdings, Celgene, Regeneron Pharmaceuticals and Sanofi highlighted as Zacks Bull and Bear of the Day

                              NVIDIA, Sotheby's Holdings, Celgene, Regeneron Pharmaceuticals and Sanofi highlighted as Zacks Bull and Bear of the Day

                                Arpita Dutt headshot

                                Celgene vs. Regeneron: Which Stock is a Better Pick?

                                Both Celgene (CELG) and Regeneron (REGN) are Zacks Rank #2 (Buy) stocks; which one of these two stocks is a better choice for investors?

                                  Zacks Industry Outlook Highlights: Bristol-Myers, Biogen, Merck, Celgene and ARIAD Pharmaceuticals

                                  Zacks Industry Outlook Highlights: Bristol-Myers, Biogen, Merck, Celgene and ARIAD Pharmaceuticals

                                    Arpita Dutt headshot

                                    Fundamentals Remain Strong in the Pharma Sector

                                    We could see several M&A agreements being announced in the coming quarters, though companies are wary of bidding wars leading to over-priced deals.

                                      The Zacks Analyst Blog Highlights: Dow Chemical, Celgene, Ford, BB&T and Sony

                                      The Zacks Analyst Blog Highlights: Dow Chemical, Celgene, Ford, BB&T and Sony

                                        Sheraz Mian headshot

                                        Top Research Reports for Celgene, Ford & Dow Chemical

                                        Today's Research Daily features new research reports on 16 major stocks, including Dow Chemical (DOW), Celgene (CELG), and Ford (F).

                                          Sheraz Mian headshot

                                          Top Research Reports for Amazon, Celgene & Chubb

                                          Today's Research Daily features new research reports on 16 major stocks, including Amazon (AMZN), Celgene (CELG) and Chubb (CB).

                                            Stock Market News for July 07, 2016

                                            Benchmarks ended in the green on Wednesday after the FOMC minutes from June meeting showed that most of the Fed policymakers were in favor of keeping rates unchanged.

                                              Stock Market News for May 10, 2016

                                              Benchmarks closed mixed on Monday after gains in healthcare stocks offset declines in energy stocks

                                                Stock Market News for April 12, 2016

                                                Benchmarks closed in the red on Monday following losses in healthcare and consumer staples stocks.

                                                  Stock Market News for March 16, 2016

                                                  Benchmarks ended mostly in the red following losses in healthcare and biotech stocks. Further, continuing decline in oil prices also weighed on key U.S. indexes